We tested the hypothesis that quinolinic acid, a tryptophan-derived N-methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32°C) or normothermia (3rC) treatments for 24 hours. Oth erwise, patients received standard neurointensive care. Quino linie acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinie acid concentrations with age, gender, GCS, time after injury,
mortality, and treatment (hypothermia versus normothermia). Quinolinie acid concentration in CSF increased maximally to 463 ± 128 nmollL (mean ± SEM) at 72 to 83 hours after TBl. Normal values for quinolinic acid concentration in CSF are less than 50 nmollL. Quinolinie acid concentration was increased 5to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinie acid. (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003). Age, gender, GCS, and treat ment (32°C versus 37°C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinie acid con centration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage. Key Words: Head injury-Macrophage Hypothermia-Inflammation-Tryptophan-Kynurenine. Traumatic brain injury (TBI) initiates a cascade of responses that may produce secondary damage to the brain and contribute to the ultimate degree of neurologic impairment. One proposed mechanism of this secondary injury is excitotoxicity via the N-methyl-D-aspartate (NMDA) receptor (Faden et aI., 1989) . Excitatory amino acids such as glutamate and aspartate are important par ticipants in early posttraumatic and postischemic excito toxicity in both animal models (Faden et aI., 1989) and humans (Bullock et aI., 1995; Persson and Hillered, 1992) .
Quinolinic acid is a metabolite of tryptophan metabo lism produced by infiltrating macrophages and activated microglia as part of the inflammatory response in the CNS (Blight et aI., 1995; Heyes et aI., 1992 Heyes et aI., , 1996 . Out side of the CNS, quinolinic acid has no known role in QUINOLlNIC ACID AFTER HEAD INJURY 6IJ mediating inflammation; however, within the CNS, quinolinic acid binds to the NMDA receptor and is neu rotoxic (Misztal et aI., 1996a; Portera-Cailliau et aI., 1997; Suse1 et aI., 1991; Yamada et aI., 1990) . The nor mal level of quinolinic acid in human CSF is less than 50 nmollL (Heyes et aI., 1995) . Quinolinic acid concentra tions as low as 100 nmollL can be neurotoxic (Giulian et aI., 1993) . Portera-Cailliau et al. (1997) reported that intrastriatal injection of 60 nmol of quinolinic acid in rats produced neuronal necrosis that was inhibited by treat ment with the NMDA antagonist MK-801. Heyes (1993) reported increases in concentrations of quinolinic acid in CSF of patients with selected CNS inflammatory disor ders, such as acquired immunodeficiency syndrome de mentia, meningitis (Heyes et aI., 1995) , and polio (Heyes et aI., 1993) . In these studies, some patients had CSF quinolinic acid concentrations greater than 10,000 nmollL. Blight et al. (1995 Blight et al. ( , 1997 , using a model of spinal cord injury in guinea pigs, showed that macrophage-derived quinolinic acid contributes to secondary damage. High levels of quinolinic acid were detected at and around the injury site where there was significant macrophage ac cumulation. In these studies, functional recovery was im proved in guinea pigs treated with either a selective in hibitor of quinolinic acid synthesis (4-chloro-3hydroxyanthranilate) or depletion of circulating macrophages.
Reports from our laboratory (Bell et aI., 1997; Clark et aI., 1996) and studies by Giulian et al. (1989) , Holmin et al. (1997) , Kossmann et al. (1996) , McClain et al. (1987) , and Balasingam and Yong (1996) , among others, have demonstrated the occurrence of a local inflamma tory response to TBI in both laboratory models and in humans. Neutrophil accumulation peaks at 24 hours (Clark et aI., 1996) and is followed by macrophage in filtration detected between 2 and 7 days (Balasingam and Yong, 1996; Holmin et aI., 1997) . Inflammatory markers have been associated with severity of injury and outcome (Bell et aI., 1997; McClain et aI., 1987) . A possible role for the macrophage-derived inflammatory metabolite quinolinic acid in the development of delayed excitotox icity after TBl, however, has not been investigated in either animal models or in clinical studies.
Finally, we reported that therapeutic hypothermia (24 hours at 32°C versus normothermia) improved outcome and attenuated the increase in the CSF concentration of the proinflammatory cytokine interleukin-l[3 in the ini tial 36 hours after severe TBI in humans (Marion et aI., 1997) . Hypothermia also attenuated leukocyte influx af ter TBl in rats (Whalen et aI., 1997) . These studies sug gest important attenuation of the inflammatory response by therapeutic hypothermia.
In this study, we tested the hypothesis that quinolinic acid concentration would be increased in ventricular CSF after severe TBI in humans and that this increase would be associated with mortality. We also tested the hypoth esis that therapeutic hypothermia would reduce CSF quinolinic acid concentration after severe TBI.
METHODS

Study population
This study included 39 patients admitted to the University of Pittsburgh Medical Center from October 1991 through April 1995 with severe closed head injury. Patients were included in this study if they were between 16 and 75 years of age with an initial Glasgow Coma Scale (GCS) score of 3 to 7, and if they were admitted within 6 hours of injury. Exclusion criteria in cluded clinical brain death (GCS score of 3 with absent brain stem reflexes), prolonged hypoxia or hypotension (oxygen saturation < 94% or systolic blood pressure < 90 mm Hg for 30 minutes or more), gunshot wound, pregnancy, unknown time of injury, normal result on a computed tomographic scan of the head, or family refusal to consent to the study. Patients were prospectively randomized to hypothermia or normothermia study groups as part of an ongoing trial of therapeutic hypo thermia (Marion et a!., 1997) .
Neurointensive care
All patients were intubated and mechanically ventilated. In vasive monitors included intraventricular, jugular venous, and arterial catheters. The management goals for all patients in cluded maintenance of cerebral perfusion pressure> 70 mm Hg by maintaining MABP between 90 and 110 mm Hg, and intra cranial pressure < 20 mm Hg. Intracranial hypertension was treated with pharmacologic paralysis and sedation. If unsuc cessful, ventricular CSF was drained intermittently and bolus intravenous infusions of mannitol were used, followed by hy perventilation and barbiturates if no mass lesion was found on computed tomography scan.
Study protocol
The patients randomized to the hypothermia group were cooled immediately after enrollment in the study using cooling blankets and nasogastric lavage with iced saline. Once the pa tients' rectal temperatures reached 33°C, they were maintained between 32° and 33°C for 24 hours, then allowed to gradually increase over the next 12 hours to temperatures of 37° to 38.5°C. The temperatures of patients in the normothermic group were maintained between 37" and 38.5°C during the entire 5-day monitoring period.
Measurement of CSF quinolinic acid
Cerebrospinal fluid samples were taken from the ventricular catheter between I and 120 hours after TBI and were stored at -70°C. Quinolinic acid concentration was measured by gas chromatography/mass spectroscopy as previously described (Heyes and Markey, 1988) . Aliquots of CSF were mixed with 200 j:LL of deionized water containing 30 pmol of e3C7l quinolinic acid as internal standard and freeze-dried overnight. Quinolinic acid and labeled quinolinic acid were derivatized to their dihexafluoroisopropanol esters, washed with 500 ILL of water, and extracted into 100 to 3000 ILL of heptane. Extracts were injected directly (1 or 2 ILL) onto a l-m deactivated silica precolumn attached to a 15-m DB5 analytical column (J & W Scientific, Folsom, CA, U.S.A.; I 10°C isothermal). Quinolinic acid was quantified using a Hewlett-Packard Model 5988 qua druple mass spectrometer operated in the electron capture nega tive chemical ionization mode with methane as reagent gas. The molecular anions of quinolinic acid (rn/z 467) and [I3C6l- quinolinic acid (m/z 473) were monitored, and each peak area at the appropriate retention time was quantified.
Statistical analysis
Cerebrospinal fluid samples were prospectively grouped into 12-hour epochs for comparison. If there was more than one sample per epoch, the values were averaged to produce a single value per patient in a given epoch. Because our data consisted of repeated observations on individuals, statistical analysis was performed using a generalized linear model that controls for the correlation between individuals (Rosner, 1984) . This model was used to assess the relationship between quinolinic acid concentrations and clinical characteristics including age, gen der, initial GCS score, and treatment (hypothermia versus nor mothermia), as well as mortality. Univariate and multivariate analyses were performed. In addition, a multiple regression model was used to assess the relationship between CSF quino linic acid and mortality.
RESULTS
Demographics of the patient population are provided in Table I . From the evaluation at 12 months after trauma, 26 of the 39 patients survived. Two patients were lost to follow-up and were categorized on the basis of their discharge evaluation. Of the 39 patients from whom CSF was available for analysis, 23 had been randomized to the normothermia group and 16 to the hypothermia group. Between 2 and 10 CSF samples were assessed per patient. A total of 230 samples were assessed with ap proximately 80% obtained during the first 3 days after TEl because CSF became less available at delayed time points owing to patient death or ventricular catheter re moval. However, of the 39 patients, 19 had samples taken beyond 3 days after injury. Normal levels of quino linic acid in CSF have been reported as less than 50 nmollL (Heyes et aI., 1995) . Cerebrospinal fluid quino linic acid concentration was 32 ± 8 nmollL (mean ± SEM) in the first 12 hours after injury, with only one value greater than 75 nmollL in our samples for this epoch. Cerebrospinal fluid levels of quinolinic acid in-J Cereb Blood Flow Metab. Vol. 18, No.6, 1998 creased steadily after 12 hours and were maximal at 72 to 83 hours, 463 ± 128 nmollL (Fig. 1) .
The univariate analyses indicated that age, gender, ini tial GCS score, and treatment (hypothermia versus nor mothermia), were not associated with quinolinic acid concentration. There was, however, a powerful associa tion between time after TBI and increased CSF quino linie acid (P < 0.0001) ( Table 2) . When all variables were entered into a multivariate regression model, again only time was associated with increased CSF quinolinic acid. A multiple regression model was used to assess the difference in quinolinic acid between those who lived and those who died, while controlling for the time that quinolinic acid was measured. This revealed that patients who died had higher levels of quinolinic acid versus survivors (P = 0.003) after controlling for the effect of time (Fig. 2) .
Despite the positive effect of hypothermia on outcome previously reported in these patients (Marion et aI., 1997) , multivariate analysis revealed no difference in quinolinic acid levels between groups. Individual values of CSF quinolinic acid in patients in the normothermia and hypothermia groups at all sampling times after injury are shown in Fig. 3 .
DISCUSSION
This is the first report of quinolinic acid in CSF after TEl in humans. Immediately after trauma, CSF quino linie acid levels were typically normal, but the ri in creased by a factor of 5 to 50 during a period of 2 to 4 days. The time course of this increase mirrors that of infiltration of macrophages into the injured brain (Bal- Yong, 1996; Holmin et aI., 1997) . Further more, it has been previously shown in vitro that quino linic acid is produced by macrophages (Heyes et aI., 1992) and microglia (Heyes et aI., 1996) stimulated by interferon-,),. Central nervous system trauma initiates re lease of inflammatory stimuli, which may induce in dolamine-2,3-dioxygenase (Blight et aI., 1993) , the rate limiting enzyme in the kynurenine pathway. This would lead to increased production of quinolinic acid from tryp tophan, which occurs in conditions of CNS inflammation (Heyes et aI., 1995) . Thus, infiltrating macrophages and possibly activated resident microglia are likely sources of quinolinic acid in human TBI (Heyes et aI., 1992 (Heyes et aI., , 1993 . The neurotoxic effect of quinolinic acid is purported to be caused by its agonist effect at the NMDA receptor (Stone, 1993) . Quinolinic acid is a potent agent for ini tiating seizures. As little as 4 nmol quinolinic acid in jected directly into the hippocampus of unanesthetized rats will produce EEG activity consistent with seizures. Models of neurologic degeneration have been developed using low-dose intrastriatal (Bazzett et aI., 1994; Susel et aI., 1991) or intraventricular (Misztal et aI., 1996a; Ya mada et aI., 1990) infusion of quinolinic acid. These models produce measurable learning deficits. Quinolinic acid is increased after experimental spinal cord injury, peaking in the lesion core at 12 days (Blight et aI., 1995) . The quinolinic acid synthesis inhibitor, 4-chloro-3hydroxyanthranilate-3,4-dioxygenase, attenuated quino linic acid accumulation in spinal cord after injury and reduced the severity of functional deficits, suggesting a substantial contribution of quinolinic acid to the devel opment of secondary damage in CNS trauma (Blight et aI., 1995) . Saito et aI. (1993) also reported accumulation of quinolinic acid in the brains of gerbils after transient ischemia.
Neurotoxicity has been reported at quinolinic acid concentrations as low as 100 nmol/L (Giulian et aI., 1993) . All but 5 of our 39 patients had at least one CSF sample with a measured quinolinic acid level greater than 100 nmollL, and several had levels greater than 1,000 nmol/L. In comparison, other human studies have shown the highest CSF quinolinic acid levels in CNS infection, with levels of 500 to 5,000 nmol/L; high levels are also found in patients after intracranial hemorrhage (Heyes et aI., 1995; Heyes, 1993) . Consistent with a putative neurotoxic role, we found a significant associa tion between mortality and increased CSF quinolinic acid concentrations after TBL It may be important that the level of this excitotoxin gradually increased and remained elevated for a pro longed time-more than 5 days in some patients_ In fact, the subacute peak of quinolinic acid in CSF 3 days after TBI in these patients may underestimate the true duration of quinolinic acid production. Several severely injured patients died in the initial 3 days, and ventricular cath eters were maintained in place more than 5 days after trauma in a limited number of patients. Thus, the dura- There was no effect of hypothermia on CSF quinolinic acid concentration. The dotted line represents the upper limit of normal for CSF quinolinic acid (50 nM). Because of the limited sample size at delayed times after injury in the hypothermia group, a log plot of all individual data points is shown. tion of elevated levels of quinolinic acid after TBI in humans is not yet known. Peak tissue levels of quinolinic acid occurred at 12 days after spinal cord injury in guinea pigs (Blight et aI., 1995) . If quinolinic acid plays a role in the development of secondary damage after TBI in humans, this suggests a rationale for trials of therapies directed at excitotoxic mechanisms, even at relatively delayed times after injury. It also suggests the possibility that for interventions such as NMDA antagonists or in hibitors of quinolinic acid synthesis, prolonged treatment may be required. This concept is supported in studies by Dietrich et aI., (1995) in a model of transient forebrain ischemia in rats showing improved efficacy using pro longed versus short-term treatment with MK-801. Simi larly, Misztal et al. (1996b) showed that administration of NMDA-receptor antagonists prevented the learning deterioration seen with long-term intraventricular infu sion of quinolinic acid.
In our study there was no correlation between eSF quinolinic acid concentrations and treatment with 24 hours of moderate hypothermia (32°C), despite the sug gested benefit of hypothermia on both eSF interleukin-1 (3 concentration and outcome for these patients (Marion et aI., 1997) . This lack of effect may represent a failure of the early transient application of hypothermia to in fluence the delayed nature of quinolinic acid production. The failure of hypothermia to attenuate eSF quinolinic acid levels despite a beneficial effect on outcome could also relate to the fact that quinolinic acid was increased predominantly in patients with mortality from severe in juries, whereas the benefit of hypothermia was largely confined to the subset of patients with GeS between 5 and 7 (Marion et aI., 1997) . Alternatively, quinolinic acid may not play a major role in the development of second ary damage after TBI in humans.
There are several possible limitations of this study. Because plasma levels of quinolinic acid were not mea sured, we cannot prove that the increase in eSF quino-1inie acid concentration was caused by production in the eNS. We also were unable to measure brain parenchy mal levels in these patients, and it is possible that another source of quinolinic acid, such as the meninges, could contribute to the large increases seen in eSF. The issue of local versus systemic production has been studied ex tensively in animal models of eNS injury, and in these models systemic quinolinic acid production is not re sponsible for the increase found in eSF (Heyes and Mor rison, 1997) . Because eSF quinolinic acid is likely to have formed in brain parenchyma, eSF measurements may actually underestimate parenchymal concentrations of quinolinic acid (Heyes et aI., 1996; Heyes and Mor rison, 1997) .
It is not a coincidence that this first report of increased quinolinic acid associated with TBI is from human sub jects. This likely results from the fact that the vast ma-J Cereb Blood Flow Metab. Vol. /8. No.6. /998 jority of animal studies of TBI are performed in rat and mouse models. Rats and mice do not produce an appre ciable quantity of quinolinic acid. Macrophages from rats and mice preferentially produce nitric oxide, rather than quinolinic acid, in response to immune stimulants, and nitric oxide is a potent inhibitor of the rate-limiting en zyme in the kynurenine pathway to quinolinic acid syn thesis, indolamine-2,3-dioxygenase (Thomas et aI., 1994) . In contrast, indolamine-2,3-dioxygenase is actu ally upregulated in guinea pig spinal cord after trauma (Blight et aI., 1993) . Because quinolinic acid is detected in large quantities in human eSF after TBI, it will be important to study its effects in appropriate animal mod els in species that produce quinolinic acid (i.e., guinea pigs, gerbils, or primates). An important role has already been reported for quinolinic acid in the pathology of spinal cord injury in guinea pigs (Blight et aI., 1995) .
In conclusion, the excitatory neurotoxin, quinolinic acid, markedly increases in eSF after severe TBI in hu mans and is strongly associated with mortality. This unique molecule appears to represent a bridge between inflammatory and excitotoxic mechanisms of damage. Additional studies are needed to address the source of production and the duration of effect, and also to deter mine the quantitative contribution of quinolinic acid to secondary damage after TBI.
